RT Journal Article
T1 Autoimmune Diseases and COVID-19 as Risk Factors for Poor Outcomes: Data on 13,940 Hospitalized Patients from the Spanish Nationwide SEMI-COVID-19 Registry.
A1 Ayala-Gutierrez, Maria Del Mar
A1 Rubio-Rivas, Manuel
A1 Romero-Gomez, Carlos
A1 Montero-Saez, Abelardo
A1 Perez-de-Pedro, Ivan
A1 Homs, Narcis
A1 Ayuso-Garcia, Blanca
A1 Cuenca-Carvajal, Carmen
A1 Arnalich-Fernandez, Francisco
A1 Beato-Perez, Jose Luis
A1 Vargas-Nuñez, Juan Antonio
A1 Letona-Gimenez, Laura
A1 Suarez-Fernandez, Carmen
A1 Mendez-Bailon, Manuel
A1 Tuñon-de-Almeida, Carlota
A1 Gonzalez-Moraleja, Julio
A1 de-Guzman-Garcia-Monge, Mayte
A1 Helguera-Amezua, Cristina
A1 Fidalgo-Montero, Maria Del Pilar
A1 Giner-Galvañ, Vicente
A1 Gil-Sanchez, Ricardo
A1 Collado-Saenz, Jorge
A1 Boixeda, Ramon
A1 Ramos Rincon, Jose Manuel
A1 Gómez-Huelgas, Ricardo
K1 COVID-19
K1 SARS-CoV-2
K1 Antirheumatic agents
K1 Autoimmune diseases
K1 Biological therapy
K1 Glucocorticoids
K1 Immune system diseases
AB (1) Objectives: To describe the clinical characteristics and clinical course of hospitalized patients with COVID-19 and autoimmune diseases (ADs) compared to the general population. (2) Methods: We used information available in the nationwide Spanish SEMI-COVID-19 Registry, which retrospectively compiles data from the first admission of adult patients with COVID-19. We selected all patients with ADs included in the registry and compared them to the remaining patients. The primary outcome was all-cause mortality during admission, readmission, and subsequent admissions, and secondary outcomes were a composite outcome including the need for intensive care unit (ICU) admission, invasive and non-invasive mechanical ventilation (MV), or death, as well as in-hospital complications. (3) Results: A total of 13,940 patients diagnosed with COVID-19 were included, of which 362 (2.6%) had an AD. Patients with ADs were older, more likely to be female, and had greater comorbidity. On the multivariate logistic regression analysis, which involved the inverse propensity score weighting method, AD as a whole was not associated with an increased risk of any of the outcome variables. Habitual treatment with corticosteroids (CSs), age, Barthel Index score, and comorbidity were associated with poor outcomes. Biological disease-modifying anti-rheumatic drugs (bDMARDs) were associated with a decrease in mortality in patients with AD. (4) Conclusions: The analysis of the SEMI-COVID-19 Registry shows that ADs do not lead to a different prognosis, measured by mortality, complications, or the composite outcome. Considered individually, it seems that some diseases entail a different prognosis than that of the general population. Immunosuppressive/immunoregulatory treatments (IST) prior to admission had variable effects.
PB MDPI
SN 2077-0383
YR 2021
FD 2021-04-23
LK http://hdl.handle.net/10668/17702
UL http://hdl.handle.net/10668/17702
LA en
NO Ayala Gutiérrez MDM, Rubio-Rivas M, Romero Gómez C, Montero Sáez A, Pérez de Pedro I, Homs N, ret al.  Autoimmune Diseases and COVID-19 as Risk Factors for Poor Outcomes: Data on 13,940 Hospitalized Patients from the Spanish Nationwide SEMI-COVID-19 Registry. J Clin Med. 2021 Apr 23;10(9):1844
DS RISalud
RD Aug 14, 2025